SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 3, 2018
Heyu Biological Technology Corporation
(Exact Name of Registrant as Specified in its Charter)
|(State or Other Jurisdiction of Incorporation)||(Commission File Number)||(IRS Employer Identification Number)|
4th Floor, No. 10 Building, Xinglin Bay Business Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip Code)
Registrant’s telephone number, including area code: (86) 158 5924 0902
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Amendment to Articles of Incorporation
On July 30, 2018, the Company amended its Articles of Incorporation with the State of Nevada in order to increase the authorized shares of common stock from 150,000,000 to 2,000,000,000 (the “Amendment”). The Board of Directors of the Company approved the Amendment on July 19, 2018.
I TEM 9.01 Financial Statement and Exhibits.
|3.1||Certificate of Amendment filed with Nevada Secretary of State dated July 30, 2018|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|Heyu Biological Technology Corporation|
|By:||/s/ Ban Siong Ang|
Ban Siong Ang
Chief Executive Officer
|Date:||August 3, 2018|